Atezolizumab
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4337 publications
Current Development of Perioperative Immune Checkpoint Inhibitor Therapy for Muscle-Invasive Bladder Cancer
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: January 19, 2026
Characteristics and outcomes of patients with HCC treated with atezolizumab/bevacizumab, stratified by second line therapy.
Journal: Future oncology (London, England)
Published: January 19, 2026
A Case of Simultaneous Resection of Single Lung and Liver Metastases with Combined Immunotherapy after Radical Surgery for Hepatocellular Carcinoma
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: January 17, 2026
Intractable Hemorrhagic Duodenal Ulcer after Atezolizumab plus Bevacizumab Treatment for Hepatic Cancer with Lymph Node Metastases-A Case Report
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: January 17, 2026
Multiagent Combo Bests Immunotherapy Alone against Colorectal Cancer.
Journal: Cancer discovery
Published: January 16, 2026
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 13, 2026
Randomized Parallel-Group Phase II Study (NEOTERIC) of Atezolizumab With or Without Tiragolumab After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 13, 2026
Subcutaneous Immunotherapy in Cancer: Where We Are Now, What It Changes, and What to Watch Next.
Journal: JCO oncology practice
Published: January 09, 2026
Pulmonary Sarcomatoid (Pleomorphic) Carcinoma Presenting As Secondary Spontaneous Pneumothorax in Diffuse Cystic Lung Disease: A Case Report.
Journal: Cureus
Published: January 09, 2026
Adjuvant chemo-immunotherapy shows comparable efficacy among mismatch-repair-deficient and mismatch-repair-proficient stage III colon cancer: an exploratory, reconstructed individual patient-level data analysis.
Journal: Journal for immunotherapy of cancer
Published: January 09, 2026
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; imlunestrant for breast cancer, tafasitamab for follicular lymphoma, atezolizumab for thymic carcinoma, retifanlimab for anal canal squamous cell carcinoma, and tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.
Journal: International journal of clinical oncology
Published: January 08, 2026
Last Updated: 02/24/2026